Lyly Le

1.6k total citations
22 papers, 1.3k citations indexed

About

Lyly Le is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lyly Le has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Lyly Le's work include Prostate Cancer Treatment and Research (5 papers), Cancer Research and Treatments (4 papers) and Cell death mechanisms and regulation (4 papers). Lyly Le is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Cancer Research and Treatments (4 papers) and Cell death mechanisms and regulation (4 papers). Lyly Le collaborates with scholars based in Canada, United States and Australia. Lyly Le's co-authors include Christian Kollmannsberger, Timothy J Wilt, Chris Coppin, Franz Porzsolt, Amit M. Oza, Lillian L. Siu, Hal W. Hirte, Malcolm J. Moore, Sébastien J. Hotte and A. Corey and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Lyly Le

22 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lyly Le Canada	13	622	544	465	281	249	22	1.3k
Tommaso Martino De Pas Italy	19	307 0.5×	943 1.7×	950 2.0×	268 1.0×	233 0.9×	45	1.5k
Glenwood D. Goss Canada	20	526 0.8×	327 0.6×	541 1.2×	396 1.4×	253 1.0×	39	1.2k
Bristi Basu United Kingdom	21	638 1.0×	249 0.5×	817 1.8×	307 1.1×	161 0.6×	85	1.5k
Fabrice Branle Switzerland	15	578 0.9×	796 1.5×	951 2.0×	209 0.7×	219 0.9×	36	1.5k
Sophia Abraham United States	8	832 1.3×	491 0.9×	569 1.2×	201 0.7×	80 0.3×	12	1.6k
Shigeki Umemura Japan	24	633 1.0×	841 1.5×	1.2k 2.5×	245 0.9×	334 1.3×	112	2.0k
Jeremy Kortmansky United States	13	434 0.7×	301 0.6×	1.0k 2.2×	269 1.0×	307 1.2×	49	1.4k
Giulia Pasello Italy	23	510 0.8×	1.1k 2.0×	1.1k 2.3×	349 1.2×	207 0.8×	165	2.0k
Toshi Menju Japan	23	642 1.0×	966 1.8×	653 1.4×	386 1.4×	120 0.5×	113	2.0k
Edgardo S. Santos United States	21	384 0.6×	524 1.0×	576 1.2×	230 0.8×	105 0.4×	101	1.2k

Countries citing papers authored by Lyly Le

Since Specialization

Citations

This map shows the geographic impact of Lyly Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lyly Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lyly Le more than expected).

Fields of papers citing papers by Lyly Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lyly Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lyly Le. The network helps show where Lyly Le may publish in the future.

Co-authorship network of co-authors of Lyly Le

This figure shows the co-authorship network connecting the top 25 collaborators of Lyly Le. A scholar is included among the top collaborators of Lyly Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lyly Le. Lyly Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Nguyen, Tai Van, et al.. (2025). Therapeutic Outcomes of Osimertinib in EGFR – Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital. Cancer Control. 32. 2935766477–2935766477. 1 indexed citations

2.

Khalaf, Daniel, Matti Annala, Sinja Taavitsainen, et al.. (2019). Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. The Lancet Oncology. 20(12). 1730–1739. 213 indexed citations

3.

Le, Lyly, et al.. (2018). CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. Hereditary Cancer in Clinical Practice. 16(1). 7–7. 8 indexed citations

4.

Eigl, Bernhard J., Kim Chi, Dongsheng Tu, et al.. (2018). A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget. 9(8). 8155–8164. 24 indexed citations

5.

Khalaf, Daniel, Arun Azad, Katherine Sunderland, et al.. (2017). A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal. 12(2). E47–52. 10 indexed citations

6.

Eigl, Bernhard J., Eric Winquist, Dongsheng Tu, et al.. (2017). A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.. Journal of Clinical Oncology. 35(15_suppl). 5021–5021. 1 indexed citations

7.

Coppin, Chris, Christian Kollmannsberger, Lyly Le, Franz Porzsolt, & Timothy J Wilt. (2011). Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. British Journal of Urology. 108(10). 1556–1563. 212 indexed citations

8.

Michels, Jorg, Susan Ellard, Lyly Le, et al.. (2009). A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Annals of Oncology. 21(2). 305–311. 18 indexed citations

9.

Coppin, Chris, Lyly Le, Timothy J Wilt, & Christian Kollmannsberger. (2008). Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews. 2011(12). CD006017–CD006017. 83 indexed citations

10.

Hotte, Sébastien J., Hal W. Hirte, Eric X. Chen, et al.. (2008). A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14(11). 3450–3455. 163 indexed citations

11.

Durán, Ignacio, Jeremy Kortmansky, Deepti Singh, et al.. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer. 95(9). 1148–1154. 260 indexed citations

12.

Le, Lyly, Malcolm J. Moore, Lillian L. Siu, et al.. (2005). Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 56(2). 154–160. 27 indexed citations

13.

Le, Lyly, Runjan Chetty, & Malcolm J. Moore. (2005). Epidermal Growth Factor Receptor Expression in Anal Canal Carcinoma. American Journal of Clinical Pathology. 124(1). 20–23. 50 indexed citations

14.

Le, Lyly, Runjan Chetty, & Malcolm J. Moore. (2005). Epidermal Growth Factor Receptor Expression in Anal Canal Carcinoma. American Journal of Clinical Pathology. 124(1). 20–23. 3 indexed citations

15.

Le, Lyly, K. Swenerton, L. Elit, et al.. (2005). Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. International Journal of Gynecological Cancer. 15(5). 799–806. 1 indexed citations

16.

Le, Lyly, Kim Chi, Scott Tyldesley, et al.. (2005). Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions. Clinical Chemistry. 51(4). 695–707. 93 indexed citations

17.

Le, Lyly, Charles Erlichman, Jake J. Thiessen, et al.. (2004). Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days. Investigational New Drugs. 22(2). 159–167. 33 indexed citations

18.

Hotte, Sébastien J., et al.. (2004). 208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial. European Journal of Cancer Supplements. 2(8). 64–64. 2 indexed citations

19.

Le, Lyly, Holger W. Hirte, Sébastien J. Hotte, et al.. (2004). Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 22(14_suppl). 2533–2533. 20 indexed citations

20.

Hoeffel, Christine, et al.. (1999). Partial Failure of Sternal Fusion in an Adolescent. Southern Medical Journal. 92(12). 1204–1206. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact